MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.86
+0.53
+0.98%
After Hours: 54.83 -0.03 -0.05% 16:11 07/08 EDT
OPEN
54.65
PREV CLOSE
54.33
HIGH
55.74
LOW
54.24
VOLUME
502.00K
TURNOVER
--
52 WEEK HIGH
56.75
52 WEEK LOW
27.77
MARKET CAP
3.78B
P/E (TTM)
-9.3575
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AGIO stock price target is 65.09 with a high estimate of 80.00 and a low estimate of 41.00.

EPS

AGIO News

More
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 6d ago
Estimating The Fair Value Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Simply Wall St. · 6d ago
Agios Pharmaceuticals (AGIO) Upgraded to Buy: Here's What You Should Know
Zacks · 06/18 17:00
Hedge Funds Standing By Agios Pharmaceuticals Inc (AGIO)
Insider Monkey · 06/18 15:46
Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020
GlobeNewswire · 06/17 21:01
Edited Transcript of AGIO.OQ earnings conference call or presentation 30-Apr-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/17 15:56
Viela Bio Gets Approval And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/16 09:13
Royalty Pharma Pulls the Off Largest IPO of 2020
MotleyFool.com · 06/16 04:00

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About AGIO

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
More

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.